Vasopressin-dependent inhibition of the C-type natriuretic peptide receptor, NPR-B/GC-B, requires elevated intracellular calcium concentrations.
about
The linker region in receptor guanylyl cyclases is a key regulatory module: mutational analysis of guanylyl cyclase CCatalytically Active Guanylyl Cyclase B Requires Endoplasmic Reticulum-mediated Glycosylation, and Mutations That Inhibit This Process Cause DwarfismFurin-mediated processing of Pro-C-type natriuretic peptideATP-independent activation of natriuretic peptide receptorsCalcium-dependent dephosphorylation mediates the hyperosmotic and lysophosphatidic acid-dependent inhibition of natriuretic peptide receptor-B/guanylyl cyclase-BRegulation of the guanylyl cyclase-B receptor by alternative splicingDephosphorylation and inactivation of NPR2 guanylyl cyclase in granulosa cells contributes to the LH-induced decrease in cGMP that causes resumption of meiosis in rat oocytes.Calcineurin regulates homologous desensitization of natriuretic peptide receptor-A and inhibits ANP-induced testosterone production in MA-10 cells.The indolocarbazole, Gö6976, inhibits guanylyl cyclase-A and -B.ATP potentiates competitive inhibition of guanylyl cyclase A and B by the staurosporine analog, Gö6976: reciprocal regulation of ATP and GTP bindingMutations in Tyr808 reveal a potential auto-inhibitory mechanism of guanylate cyclase-B regulation.Homologous and heterologous desensitization of guanylyl cyclase-B signaling in GH3 somatolactotropesThe natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment.Critical roles of the guanylyl cyclase B receptor in endochondral ossification and development of female reproductive organs.Designer natriuretic peptides: a vision for the future of heart failure therapeutics.Prolonged atrial natriuretic peptide exposure stimulates guanylyl cyclase-a degradation.Adenine nucleotides decrease the apparent Km of endogenous natriuretic peptide receptors for GTP.Novel bifunctional natriuretic peptides as potential therapeutics.Mass spectrometric identification of phosphorylation sites in guanylyl cyclase A and B.Natriuretic peptide activation of extracellular regulated kinase 1/2 (ERK1/2) pathway by particulate guanylyl cyclases in GH3 somatolactotropes.Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure.Skeletal overgrowth-causing mutations mimic an allosterically activated conformation of guanylyl cyclase-B that is inhibited by 2,4,6,-trinitrophenyl ATP.A Glutamate-Substituted Mutant Mimics the Phosphorylated and Active Form of Guanylyl Cyclase-A.
P2860
Q24647874-FFE5914C-3D25-4335-9B50-AF0964B9EB63Q28116378-8F8FAEE6-9D25-43DF-B4A2-AEA987333CE3Q28203022-764D8153-6A5A-4075-8C14-C385C0CBA268Q28252448-4E3B9D19-49FE-446B-807D-69876F5425A7Q28282496-ECB39D3A-FFA7-4AE2-95F4-24C1969BC9A9Q28508538-184EB307-E961-4935-B3D8-9518055FA3D3Q34341855-0A28B2CF-4CAE-4614-A9FB-47DFD3042920Q34372490-B585786C-987E-4CE4-9592-BE060C0838BEQ35287220-8421AEED-21BA-45E9-AF7F-8CFFDC65D685Q35310662-A466EEC5-4FA2-4FC4-AFAB-0E24402E2D94Q36904037-21A62CA8-5285-4677-98AC-C82D93861EF3Q37578504-BB17485D-0D5F-42F0-8D61-DE6B4A243C53Q37583865-F81E69E3-C412-4DA5-8EF4-64092F64AAB9Q37693870-661DF288-22EA-4EB0-8BB2-327A87D2C315Q37911516-4E614D18-E314-4EE2-9781-9F24F460FB1AQ39716241-69F564EB-989E-4A65-B263-DA67C408C706Q40082312-7E83346F-5C4F-471B-B273-2A87BBC4E484Q40455345-5B552B12-2039-45E6-BEDC-F5224550712CQ41223771-9246B7FB-954C-48FB-955B-8E65F51012E5Q41581124-54B02AA1-0F64-4C23-85A1-9818EF2B00C3Q47855200-D029E0A8-3B5E-4D02-AB5E-F9E7497B5B03Q50441113-CC795514-5ED1-4B1D-9D32-F649863B8ABBQ51053075-F07263DE-D857-4D07-97E7-236B722537BC
P2860
Vasopressin-dependent inhibition of the C-type natriuretic peptide receptor, NPR-B/GC-B, requires elevated intracellular calcium concentrations.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Vasopressin-dependent inhibiti ...... llular calcium concentrations.
@en
Vasopressin-dependent inhibiti ...... llular calcium concentrations.
@nl
type
label
Vasopressin-dependent inhibiti ...... llular calcium concentrations.
@en
Vasopressin-dependent inhibiti ...... llular calcium concentrations.
@nl
prefLabel
Vasopressin-dependent inhibiti ...... llular calcium concentrations.
@en
Vasopressin-dependent inhibiti ...... llular calcium concentrations.
@nl
P2860
P356
P1476
Vasopressin-dependent inhibiti ...... llular calcium concentrations.
@en
P2093
Lincoln R Potter
Sarah E Abbey
P2860
P304
42423-42430
P356
10.1074/JBC.M206686200
P407
P577
2002-08-23T00:00:00Z